Farzad Najafipour

Farzad Najafipour

Auto-generated profile, based on publicly available information

Farzad Najafipour

Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2012 in Biology of Sport
Verified
Journal Article
Closed access
AYAbbas Yavari
Abbas Yavari
FNFarzad Najafipoor
Farzad Najafipoor
AAAkbar Aliasgharzadeh
Akbar Aliasgharzadeh
MNMitra Niafar
Mitra Niafar
MMMajid Mobasseri
Majid Mobasseri
Expired Registration Recovery Policy

6 March 2015 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
NANasser Aghamohammadzadeh
Nasser Aghamohammadzadeh
MNMitra Niafar
Mitra Niafar
EAElham Dalir Abdolahinia
Elham Dalir Abdolahinia
FNFarzad Najafipour
Farzad Najafipour
SGSaeed Mohamadzadeh Gharebaghi
Saeed Mohamadzadeh Gharebaghi
HAHamidreza Ahadi
Hamidreza Ahadi
Pioglitazone is one of the antidiabetic agents used in the management of type 2 diabetes mellitus (DM). The effect of pioglitazone on blood glucose, lipid profile, liver enzymes and weight has been shown with conflicting results. In this study we aim to evaluate the effect of pioglitazone on the weight, lipid profile and liver enzymes in patients with DM. In this single-arm clinical trial, 110 poorly controlled diabetic type 2 patients (63.6% female with mean age of 54.26 ± 8.96 years) who were on maximal dosage of metformin and glibenclamide were enrolled. Patients were treated with pioglitazone for 3 months and laboratory. Fasting blood sugar (FBS), haemoglobin A1C (HbA1C), cholesterol, triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL), alkaline phosphatase (ALK-P), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and weight changes were measured before and at the end of the study. The levels of FBS (p < 0.001), HbA1c (p < 0.001), triglyceride (p = 0.001), ALT (p = 0.005) and ALK-P (p = 0.001) were significantly decreased, but weight was significantly increased (p < 0.001) after the intervention. There were no significant difference in cholesterol, LDL and HDL values before and after study. Although pioglitazone causes a significant decrease in FBS, HbA1C and triglyceride levels, it is associated with weight gain, which would limit its utility. IRCT registration code: IRCT201209276712N2

1 September 2008 in Annals of Saudi Medicine
Verified
Journal Article
Open access
FNFarzad Najafipour
Farzad Najafipour
AAAkbar Aliasgarzadeh
Akbar Aliasgarzadeh
NANaser Aghamohamadzadeh
Naser Aghamohamadzadeh
ABAmir Bahrami
Amir Bahrami
MMMajid Mobasri
Majid Mobasri
MKManouchehr Khoshbatenb
Manouchehr Khoshbatenb
Iron overload is a major problem in patients with beta-thalassemia major, and it has many structural and metabolic consequences. The aim of this study was evaluation of endocrine disturbances in patients with beta-thalassemia major who were older than 10 years of age. In this cross-sectional study, investigators collected demographic data and medical histories, as well as menstrual history in females, from the medical records of 56 patients with beta-thalassemia major. Patients were examined to determine their pubertal status and the standard deviation score for height for evaluation of short stature. For evaluation of glucose tolerance, a fasting blood glucose and oral glucose tolerance test were performed. Evidence for diabetes mellitus was based on American Diabetes Association and World Health Organization criteria. Serum levels of calcium, phosphorous, thyroid-stimulating hormone, free thyroxin, luteinizing hormone and follicular-stimulating hormone, and estradiol in girls and testosterone in boys were measured. The mean and standard deviation for age in the 56 patients (36 males and 20 females) was 15.62±4.44 years. Diabetes mellitus was present in 5 patients (8.9%), impaired fasting glucose was found in 16 patients (28.6%) and an impaired glucose tolerance test was found in 4 patients (7.1%). Short stature (standard deviation score <−2) was seen in 25 (70%) boys and 14 (73%) girls. Impaired puberty was found in 40 patients (71%). Hypocalcaemia and primary overt hypothyroidism were present in 23 (41%) and 9 patients (16%), respectively. Only eight patients (14.3%) had no endocrine abnormalities. Despite therapy with deferoxamine to treat iron overload, the risk of secondary endocrine dysfunction remained high. Hypogonadism was one of the most frequent endocrine complications. Impaired glucose tolerance, short stature, hypocalcemia, subclinical and overt hypothyroidism are also frequent.

1 December 2010
Verified
Journal Article
Open access
MKManouchehr Khoshbaten
Manouchehr Khoshbaten
AAAkbar Aliasgarzadeh
Akbar Aliasgarzadeh
KMKoorosh Masnadi
Koorosh Masnadi
MTMohammad K. Tarzamani
Mohammad K. Tarzamani
SFSara Farhang
Sara Farhang
FNFarzad Najafipoor
Farzad Najafipoor
Background and Aims: Non-alcoholic fatty liver change is a common disease of the liver in which oxidative stress plays a basic role. Studies are largely focused on protecting the liver by means of anti-oxidative material. The aim of this study is to evaluate the role of N-acetylcysteine in the process of liver injury. Methods: Thirty patients with non-alcoholic fatty liver steatosis were randomly selected to receive either N-acetylcysteine or vitamin C. Liver function tests (alanine aminotransfrase, aspartate aminotransfrase and alkaline phosphatase) were measured as well as the grade of steatosis, the pattern of its echogenicity, the span of the liver and the spleen and the portal vein diameter before the intervention. Patients were followed up using the same method of evaluation repeated in the first, second and third months. Results: The mean age (SD) was 40.1(12.4) in patients receiving NAC and 46(10.4) years in patients receiving vitamin C (P = 0.137). NAC resulted in a significant decrease of serum alanine aminotransfrase after three months, compared to vitamin C. This effect was independent of the grade of steatosis in the initial diagnosis. NAC was able to significantly decrease the span of the spleen. Conclusions: N-acetylcysteine can improve liver function in patients with non-alcoholic fatty liver disease. Better results may be achievable in a longer follow up.

1 January 2010 in Saudi Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
SFSara Farhang
Sara Farhang
MKManouchehr Khoshbaten
Manouchehr Khoshbaten
AAAkbar Aliasgarzadeh
Akbar Aliasgarzadeh
KMKoorosh Masnadi
Koorosh Masnadi
MTMohammad K Tarzamani
Mohammad K Tarzamani
FNFarzad Najafipoor
Farzad Najafipoor
Background/Aim: Therapeutic interventions in nonalcoholic fatty liver disease are limited, while anti-oxidative materials have shown benefits in animal models. This study aimed to evaluate grape seed extract as an anti-oxidative material in this process. Therapeutic effects of grape seed extract were evaluated in comparison to vitamin C in a double-blind setting. Materials and Methods: Fifteen patients were enrolled in each group. Liver function tests were done; also, grade of steatosis and pattern of echogenicity of the liver were determined. Patients were followed up by the same evaluation repeated in first, second and third months. Results: Mean age ± standard deviation was 43.2 ? 10.3 years. Grape seed extract (GSE) significantly improved the grade of fatty liver change; and resulted in significant decrease in alanine aminotransferase in patients receiving the concentrate compared to those receiving vitamin C independently, from the initial grade of steatosis. Conclusions: This study describes the beneficial effect of using grape seed extract for three months in patients with nonalcoholic fatty liver disease. These results may improve with a longer period of follow-up.

20 February 2023 in Health Science Reports
Verified
Journal Article
Open access
HJHabib Jalilian
Habib Jalilian
SHSomayeh Heydari
Somayeh Heydari
AIAli Imani
Ali Imani
MSMozhgan Salimi
Mozhgan Salimi
NMNazanin Mir
Nazanin Mir
FNFarzad Najafipour
Farzad Najafipour
Background and Aims: Type 2 diabetes mellitus (T2DM) is a prevalent public health problem worldwide, and the economic burden of the disease poses one of the main challenges for health systems in low‐ and middle‐income countries. This study aimed to estimate the economic burden of T2DM in Iran, in 2018.Methods: This was a cost‐of‐illness study. Three hundred and seventy‐five patients with T2DM who were referred to Imam Reza and Sina's educational and therapeutic centers and Asad Abadi clinic in Tabriz, Iran, in 2018 were included. A researcher‐constructed checklist was used for data collection. Data were analyzed using EXCEL and SPSS software version 22.Results: Total economic burden of diabetes was estimated at 152,443,862,480.3 (purchasing power parity [PPP], Current International $) (approximately 7.69% of GDP, PPP, Current International $). The mean total direct and indirect costs were 11,278.68 (PPP) (62.35% of mean total cost) and 6808.88 (PPP, Current International $) (37.64% of the total cost), respectively. The mean total direct medical cost and the direct nonmedical cost were 10,819.43 (PPP, Current International $) (59.81% of mean total cost) and 459.24 (PPP, Current International $) (2.53% of mean total cost) per patient, respectively. Besides, the mean direct medical cost was 6.18 times the total per capita expenditure on health, and the total direct medical cost was 8.9% times the total expenditure on health.Conclusion: Diabetes imposes a substantial economic burden on patients, health systems, and the whole economy. Besides, since the cost of the disease in patients treated with insulin and those with diabetes complications is significantly higher, the reinforcement of self‐care measures and focusing on modifying lifestyle (dietary modification and physical activity) in patients with T2DM can significantly reduce the costs of the disease.